|
MD Anderson residual cancer burden index for post-neoadjuvant breast neoplasm (assessment scale)
MD Anderson residual cancer burden index for post-neoadjuvant breast neoplasm
Developed at MD Anderson, the residual cancer burden index is a method of measuring residual cancer of post-neoadjuvant breast neoplasms. It is a calculation based on the size of the viable neoplasm, cellularity of the neoplasm and lymph node involvement.
Id1407077008
StatusPrimitive